117 related articles for article (PubMed ID: 17139156)
1. [How I was enticed into molecular toxicology].
Kamataki T
Yakugaku Zasshi; 2006 Dec; 126(12):1309-18. PubMed ID: 17139156
[TBL] [Abstract][Full Text] [Related]
2. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
Kamataki T; Fujieda M; Kiyotani K; Iwano S; Kunitoh H
Biochem Biophys Res Commun; 2005 Dec; 338(1):306-10. PubMed ID: 16176798
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
[TBL] [Abstract][Full Text] [Related]
5. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of CYP2A6 in relation to cancer.
Kamataki T; Nunoya K; Sakai Y; Kushida H; Fujita K
Mutat Res; 1999 Jul; 428(1-2):125-30. PubMed ID: 10517986
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
Takeuchi H; Saoo K; Yokohira M; Ikeda M; Maeta H; Miyazaki M; Yamazaki H; Kamataki T; Imaida K
Cancer Res; 2003 Nov; 63(22):7581-3. PubMed ID: 14633670
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
Miyazaki M; Yamazaki H; Takeuchi H; Saoo K; Yokohira M; Masumura K; Nohmi T; Funae Y; Imaida K; Kamataki T
Carcinogenesis; 2005 Nov; 26(11):1947-55. PubMed ID: 15958517
[TBL] [Abstract][Full Text] [Related]
11. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells.
Tiano HF; Wang RL; Hosokawa M; Crespi C; Tindall KR; Langenbach R
Carcinogenesis; 1994 Dec; 15(12):2859-66. PubMed ID: 8001247
[TBL] [Abstract][Full Text] [Related]
12. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108.
Kushida H; Fujita K; Suzuki A; Yamada M; Nohmi T; Kamataki T
Mutat Res; 2000 Nov; 471(1-2):135-43. PubMed ID: 11080669
[TBL] [Abstract][Full Text] [Related]
13. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
14. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
[TBL] [Abstract][Full Text] [Related]
15. Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
Tiano HF; Hosokawa M; Chulada PC; Smith PB; Wang RL; Gonzalez FJ; Crespi CL; Langenbach R
Carcinogenesis; 1993 Jul; 14(7):1421-7. PubMed ID: 8330360
[TBL] [Abstract][Full Text] [Related]
16. An association of CYP2A6 genotype and smoking topography.
Strasser AA; Malaiyandi V; Hoffmann E; Tyndale RF; Lerman C
Nicotine Tob Res; 2007 Apr; 9(4):511-8. PubMed ID: 17454707
[TBL] [Abstract][Full Text] [Related]
17. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
[TBL] [Abstract][Full Text] [Related]
18. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13.
Jalas JR; Ding X; Murphy SE
Drug Metab Dispos; 2003 Oct; 31(10):1199-202. PubMed ID: 12975327
[TBL] [Abstract][Full Text] [Related]
19. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
Yuan JM; Nelson HH; Carmella SG; Wang R; Kuriger-Laber J; Jin A; Adams-Haduch J; Hecht SS; Koh WP; Murphy SE
Carcinogenesis; 2017 Apr; 38(4):411-418. PubMed ID: 28182203
[TBL] [Abstract][Full Text] [Related]
20. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
